Placeholder Banner

ICH: BIO Submits Comments on S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines

April 1, 2019

BIO submitted comments to the Food and Drug Administration (FDA) on the draft guidance, S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines.

BIO's comments address the use of datasets, in vitro nonclinical investigations, and the necessity of repeating juvenile toxicity studies on a prodrug of an approved drug when there may or may not be existing adult toxicity data for the prodrug.

Download Full Comments Below
BIO Comments On S11 Nonclinical Safety Testing In Support Of Development Of Pediatric Medicines FDA-2018-D-4524
Read full comment letter below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden…